187 related articles for article (PubMed ID: 10444166)
21. Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues.
Hébrard C; Dumontet C; Jordheim LP
Cancer Gene Ther; 2009 Jul; 16(7):541-50. PubMed ID: 19343063
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.
Jordheim LP; Cros E; Gouy MH; Galmarini CM; Peyrottes S; Mackey J; Perigaud C; Dumontet C
Clin Cancer Res; 2004 Aug; 10(16):5614-21. PubMed ID: 15328204
[TBL] [Abstract][Full Text] [Related]
23. High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Löfgren C; Albertioni F; Paul C
Ther Drug Monit; 2005 Oct; 27(5):641-6. PubMed ID: 16175139
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
Jordheim LP; Galmarini CM; Dumontet C
Cancer Chemother Pharmacol; 2006 Oct; 58(4):547-54. PubMed ID: 16463058
[TBL] [Abstract][Full Text] [Related]
25. IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.
Cividini F; Filoni DN; Pesi R; Allegrini S; Camici M; Tozzi MG
Biochim Biophys Acta; 2015 Jul; 1850(7):1354-61. PubMed ID: 25857773
[TBL] [Abstract][Full Text] [Related]
26. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Iwasaki H; Huang P; Keating MJ; Plunkett W
Blood; 1997 Jul; 90(1):270-8. PubMed ID: 9207462
[TBL] [Abstract][Full Text] [Related]
27. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Bergman AM; Giaccone G; van Moorsel CJ; Mauritz R; Noordhuis P; Pinedo HM; Peters GJ
Eur J Cancer; 2000 Oct; 36(15):1974-83. PubMed ID: 11000580
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
Reiman T; Graham KA; Wong J; Belch AR; Coupland R; Young J; Cass CE; Mackey JR
Leukemia; 2002 Sep; 16(9):1886-7. PubMed ID: 12200718
[No Abstract] [Full Text] [Related]
29. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
Adema AD; Smid K; Losekoot N; Honeywell RJ; Verheul HM; Myhren F; Sandvold ML; Peters GJ
Invest New Drugs; 2012 Oct; 30(5):1908-16. PubMed ID: 22002019
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
[TBL] [Abstract][Full Text] [Related]
31. Seeking the nucleoside transporter.
Wiley JS
Nat Med; 1997 Jan; 3(1):25-6. PubMed ID: 8986733
[No Abstract] [Full Text] [Related]
32. 2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
Schirmer M; Michlmayr G; Geisen F; Konwalinka G
Leukemia; 1996 Jul; 10(7):1253-4. PubMed ID: 8684013
[No Abstract] [Full Text] [Related]
33. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
[TBL] [Abstract][Full Text] [Related]
34. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Hapke DM; Stegmann AP; Mitchell BS
Cancer Res; 1996 May; 56(10):2343-7. PubMed ID: 8625309
[TBL] [Abstract][Full Text] [Related]
35. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.
Pettitt AR; Sherrington PD; Cawley JC
Br J Haematol; 1999 Sep; 106(4):1049-51. PubMed ID: 10520012
[TBL] [Abstract][Full Text] [Related]
36. Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
Lachmann N; Czarnecki K; Brennig S; Phaltane R; Heise M; Heinz N; Kempf H; Dilloo D; Kaever V; Schambach A; Heuser M; Moritz T
Leukemia; 2015 Nov; 29(11):2266-9. PubMed ID: 25921248
[No Abstract] [Full Text] [Related]
37. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Styczynski J; Wysocki M; Debski R; Czyzewski K; Balwierz W; Juraszewska E; Matysiak M; Malinowska I; Stanczak E; Sońta-Jakimczyk D; Szczepanski T; Wachowiak J; Konatkowska B; Balcerska A; Ploszynska A; Kowalczyk J; Stefaniak J; Badowska W; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M
Neoplasma; 2005; 52(1):74-8. PubMed ID: 15739031
[TBL] [Abstract][Full Text] [Related]
38. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.
Obata T; Endo Y; Tanaka M; Uchida H; Matsuda A; Sasaki T
Jpn J Cancer Res; 2001 Jul; 92(7):793-8. PubMed ID: 11473731
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
Grant S; Turner A; Nelms P; Yanovich S
Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
[TBL] [Abstract][Full Text] [Related]
40. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Delannoy A; Hanique G; Ferrant A
N Engl J Med; 1993 Mar; 328(11):812; author reply 813. PubMed ID: 8094888
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
